Yip1 domain family member 2Genealiases: FinGER2 · YIPFbeta3B · Yip5C
Q-omics provides the consensus-scored YIPF2 profile across patient tissues and cancer cell-line models. YIPF2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, YIPF2 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, YIPF2 protein abundance shows 27,501 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight UVM, BLCA, and UCEC as cancer lineages where YIPF2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for YIPF2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes YIPF2 survival associations across molecular data types. YIPF2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible YIPF2 RNA expression–survival associations across cancer types. High YIPF2 expression shows unfavorable associations in UVM, LGG, KICH, LUSC, READ and BLCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for YIPF2 RNA expression.
This table summarizes YIPF2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 10. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for YIPF2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. YIPF2 shows higher tumor expression in BLCA, COAD, HNSC, LIHC, LUAD and BRCA. The BLCA box plot shows higher YIPF2 RNA expression in tumor versus normal tissue (log2 FC = +1.173, t-test p < 0.001).
This table shows molecular features associated with YIPF2 in patient tissues and cancer cell lines. In patient samples, YIPF2 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, YIPF2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
